{"id":33627,"date":"2025-05-27T09:35:18","date_gmt":"2025-05-27T07:35:18","guid":{"rendered":"https:\/\/ggba.swiss\/syrhatech-raises-chf-4-5-million-to-innovate-in-hyaluronic-acid-medical-devices\/"},"modified":"2025-05-27T09:37:02","modified_gmt":"2025-05-27T07:37:02","slug":"syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/","title":{"rendered":"Syrhatech l\u00e8ve CHF 4,5 millions pour innover dans les dispositifs m\u00e9dicaux \u00e0 base d&rsquo;acide hyaluronique"},"content":{"rendered":"\n<p>La soci\u00e9t\u00e9 franco-suisse <a href=\"https:\/\/www.syrhatech.com\/\">Syrhatech<\/a> a annonc\u00e9 la cl\u00f4ture d&rsquo;un tour de table de CHF 4,5 millions, soutenu par des investisseurs strat\u00e9giques. Bas\u00e9e \u00e0 Plan-les-Ouates \u00e0 Gen\u00e8ve, et disposant d&rsquo;un site de production \u00e0 Chamb\u00e9ry, en France, la soci\u00e9t\u00e9 est une organisation de d\u00e9veloppement et de fabrication sous contrat (CDMO) sp\u00e9cialis\u00e9e dans les dispositifs m\u00e9dicaux injectables \u00e0 base d&rsquo;acide hyaluronique (AH) et d&rsquo;autres biopolym\u00e8res.<\/p>\n\n\n\n<p>Ce nouvel investissement marque une \u00e9tape importante pour Syrhatech, qui acc\u00e9l\u00e8re ainsi son expansion dans les domaines de la recherche et de la production. Les fonds seront utilis\u00e9s pour renforcer son \u00e9quipe de R&amp;D bas\u00e9e \u00e0 Gen\u00e8ve et pour installer de nouvelles capacit\u00e9s de production sur le site de Chamb\u00e9ry. Ces d\u00e9veloppements visent \u00e0 r\u00e9pondre \u00e0 la demande mondiale croissante de produits injectables \u00e0 base d&rsquo;AH dans des secteurs tels que la dermatologie esth\u00e9tique, l&rsquo;orthop\u00e9die et l&rsquo;ophtalmologie, d&rsquo;autres domaines th\u00e9rapeutiques devant suivre.<\/p>\n\n\n\n<p>Fond\u00e9e en 2015, Syrhatech s&rsquo;est impos\u00e9e comme un acteur cl\u00e9 dans le paysage europ\u00e9en des dispositifs m\u00e9dicaux, gr\u00e2ce \u00e0 sa <a href=\"https:\/\/www.syrhatech.com\/intexhya-exclusive-technology\/\">technologie exclusive INTEXHYA<\/a> et \u00e0 son engagement fort en faveur de la qualit\u00e9. Certifi\u00e9e ISO 13485, la soci\u00e9t\u00e9 offre des services de d\u00e9veloppement de bout en bout, de la formulation et des tests analytiques \u00e0 la fabrication st\u00e9rile. Les investissements r\u00e9cents dans des infrastructures de pointe, notamment l&rsquo;installation d&rsquo;un nouvel autoclave, soulignent encore davantage la capacit\u00e9 de Syrhatech \u00e0 passer \u00e0 l&rsquo;\u00e9chelle industrielle.<\/p>\n\n\n\n<p>Ce tour de table offre \u00e9galement aux investisseurs l&rsquo;opportunit\u00e9 de soutenir une entreprise \u00e0 fort potentiel \u00e0 la crois\u00e9e de la biotechnologie et de la technologie m\u00e9dicale. Alors que la demande de produits injectables \u00e0 base d&rsquo;AH continue de cro\u00eetre, sous l&rsquo;effet des changements d\u00e9mographiques et des innovations dans les applications th\u00e9rapeutiques, Syrhatech est bien positionn\u00e9e pour tirer parti de cette tendance gr\u00e2ce \u00e0 son expertise scientifique et \u00e0 sa flexibilit\u00e9 de fabrication.<\/p>\n\n\n\n<p>Gr\u00e2ce \u00e0 ce financement, Syrhatech renforce sa position de p\u00f4le d&rsquo;innovation europ\u00e9en dans le domaine des biomat\u00e9riaux injectables. En d\u00e9veloppant ses sites de Gen\u00e8ve et de Chamb\u00e9ry, l&rsquo;entreprise renforce la dynamique transfrontali\u00e8re de l&rsquo;\u00e9cosyst\u00e8me des sciences de la vie en Suisse romande et illustre la capacit\u00e9 de la r\u00e9gion \u00e0 favoriser le d\u00e9veloppement d&rsquo;entreprises de technologie m\u00e9dicale agiles et pr\u00eates \u00e0 l&rsquo;export.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 genevoise Syrhatech a lev\u00e9 CHF 4,5 millions pour d\u00e9velopper sa R&#038;D et la fabrication de dispositifs m\u00e9dicaux injectables \u00e0 base d&rsquo;acide hyaluronique afin de r\u00e9pondre \u00e0 la demande croissante en dermatologie, orthop\u00e9die et ophtalmologie.<\/p>\n","protected":false},"author":6,"featured_media":33624,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1216,1148,1188,1170,1181,1163],"class_list":["post-33627","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-additive-manufacturing-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-manufacturing-fr-2","tag-medical-devices-fr","tag-medtech-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Syrhatech l\u00e8ve CHF 4,5 millions | GGBa<\/title>\n<meta name=\"description\" content=\"Syrhatech a lev\u00e9 CHF 4,5 millions pour d\u00e9velopper sa R&amp;D et la fabrication de dispositifs m\u00e9dicaux injectables \u00e0 base d&#039;acide hyaluronique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syrhatech l\u00e8ve CHF 4,5 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"Syrhatech a lev\u00e9 CHF 4,5 millions pour d\u00e9velopper sa R&amp;D et la fabrication de dispositifs m\u00e9dicaux injectables \u00e0 base d&#039;acide hyaluronique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-27T07:35:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T07:37:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Syrhatech l\u00e8ve CHF 4,5 millions pour innover dans les dispositifs m\u00e9dicaux \u00e0 base d&rsquo;acide hyaluronique\",\"datePublished\":\"2025-05-27T07:35:18+00:00\",\"dateModified\":\"2025-05-27T07:37:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/\"},\"wordCount\":431,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg\",\"keywords\":[\"Additive Manufacturing\",\"Financing\",\"Healthcare\",\"Manufacturing\",\"Medical Devices\",\"Medtech\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/\",\"name\":\"Syrhatech l\u00e8ve CHF 4,5 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg\",\"datePublished\":\"2025-05-27T07:35:18+00:00\",\"dateModified\":\"2025-05-27T07:37:02+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Syrhatech a lev\u00e9 CHF 4,5 millions pour d\u00e9velopper sa R&D et la fabrication de dispositifs m\u00e9dicaux injectables \u00e0 base d'acide hyaluronique.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Les CHF 4,5 millions lev\u00e9s par Syrhatech permettront d'acc\u00e9l\u00e9rer la R&D et la production de dispositifs m\u00e9dicaux injectables \u00e0 base d'acide hyaluronique \u00e0 Gen\u00e8ve et \u00e0 Chamb\u00e9ry. | \u00a9 Syrhatech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syrhatech l\u00e8ve CHF 4,5 millions pour innover dans les dispositifs m\u00e9dicaux \u00e0 base d&#8217;acide hyaluronique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syrhatech l\u00e8ve CHF 4,5 millions | GGBa","description":"Syrhatech a lev\u00e9 CHF 4,5 millions pour d\u00e9velopper sa R&D et la fabrication de dispositifs m\u00e9dicaux injectables \u00e0 base d'acide hyaluronique.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/","og_locale":"fr_FR","og_type":"article","og_title":"Syrhatech l\u00e8ve CHF 4,5 millions | GGBa","og_description":"Syrhatech a lev\u00e9 CHF 4,5 millions pour d\u00e9velopper sa R&D et la fabrication de dispositifs m\u00e9dicaux injectables \u00e0 base d'acide hyaluronique.","og_url":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-05-27T07:35:18+00:00","article_modified_time":"2025-05-27T07:37:02+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Syrhatech l\u00e8ve CHF 4,5 millions pour innover dans les dispositifs m\u00e9dicaux \u00e0 base d&rsquo;acide hyaluronique","datePublished":"2025-05-27T07:35:18+00:00","dateModified":"2025-05-27T07:37:02+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/"},"wordCount":431,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg","keywords":["Additive Manufacturing","Financing","Healthcare","Manufacturing","Medical Devices","Medtech"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/","url":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/","name":"Syrhatech l\u00e8ve CHF 4,5 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg","datePublished":"2025-05-27T07:35:18+00:00","dateModified":"2025-05-27T07:37:02+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Syrhatech a lev\u00e9 CHF 4,5 millions pour d\u00e9velopper sa R&D et la fabrication de dispositifs m\u00e9dicaux injectables \u00e0 base d'acide hyaluronique.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Syrahtech-1180x811-1.jpeg","width":1180,"height":811,"caption":"Les CHF 4,5 millions lev\u00e9s par Syrhatech permettront d'acc\u00e9l\u00e9rer la R&D et la production de dispositifs m\u00e9dicaux injectables \u00e0 base d'acide hyaluronique \u00e0 Gen\u00e8ve et \u00e0 Chamb\u00e9ry. | \u00a9 Syrhatech"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/syrhatech-leve-chf-45-millions-pour-innover-dans-les-dispositifs-medicaux-a-base-dacide-hyaluronique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Syrhatech l\u00e8ve CHF 4,5 millions pour innover dans les dispositifs m\u00e9dicaux \u00e0 base d&#8217;acide hyaluronique"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=33627"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33627\/revisions"}],"predecessor-version":[{"id":33629,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33627\/revisions\/33629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/33624"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=33627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=33627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=33627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}